Concentration of Ampicillin / Sulbactam and Amoxicillin / Clavulanic Acid in the Blood During Renal Replacement Therapy in Longterm Renal Replacement Therapy Patients

• Status: Completed
• Trial end date: 2017-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The study will be conducted to investigate the pharmacokinetics of ampicillin / sulbactam and amoxicillin/clavulanic acid during intermittent haemodialysis.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Medical University of Vienna
• Treatments: Amoxicillin; Ampicillin; Clavulanic Acid; Clavulanic Acids; Sulbactam; Sultamicillin

Criteria

Inclusion Criteria:

• Age >18 years

• Suspected or proven bacterial infection requiring parenteral antibiotic therapy.

• Renal replacement therapy (HD)

Exclusion Criteria:

• Known hypersensitivity to ampicillin / sulbactam, amoxicillin / clavulanic acid or other beta-lactames, or severe hypersensitivity (anaphylactic reaction) to beta-lactam antibacterial agents.

• An expected survival of less than two days.

• Known pregnancy

• Co-administration of one of the following drugs: probenecid which cannot be discontinued for the duration of the study

• Ampicillin / sulbactam respectively amoxicillin / clavulanic acid as monotherapy for resistant species or fungal infections.

• Other reasons opposing the study participation on the discretion of the investigators.